Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • Keros Therapeutics' Net Cash Flow fell 97.40% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.8 million, marking a year-over-year decrease of 33.02%. This contributed to the annual value of $229.0 million for FY2024, which is 340.56% up from last year.
  • Per Keros Therapeutics' latest filing, its Net Cash Flow stood at $3.3 million for Q3 2025, which was up 110.74% from -$30.3 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Net Cash Flow peaked at $160.6 million during Q1 2025, and registered a low of -$36.6 million during Q2 2024.
  • Its 3-year average for Net Cash Flow is $37.7 million, with a median of $29.2 million in 2024.
  • The largest annual percentage gain for Keros Therapeutics' Net Cash Flow in the last 5 years was 5,071.22% (2023), contrasted with its biggest fall of 243.87% (2023).
  • Over the past 5 years, Keros Therapeutics' Net Cash Flow (Quarterly) stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then climbed by 9.17% to $43.3 million in 2023, then tumbled by 32.38% to $29.2 million in 2024, then crashed by 97.40% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, -$30.3 million for Q2 2025, and $160.6 million during Q1 2025.